Anna Carta

Prof. Anna Carta

University of Cagliari (Italy)
orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2007 in Neurotoxicity Research
Verified
Journal Article
Closed access
PDF file
Nicola SimolaNicola Simola
Nicola Simola
Micaela MorelliMicaela Morelli
Micaela Morelli
Anna CartaAnna Carta
Anna Carta

1 August 2017 in Progress in Neurobiology
Verified
Journal Article
Closed access
VJValerie Joers
Valerie Joers
MTMariadeLourdes Tansey
MariadeLourdes Tansey
GMGiovanna Mulas
Giovanna Mulas
Anna CartaAnna Carta
Anna Carta


2 March 2009 in European Journal of Neuroscience
Verified
Journal Article
Closed access
PDF file
NSNicoletta Schintu
Nicoletta Schintu
LFLucia Frau
Lucia Frau
MIMarcello Ibba
Marcello Ibba
PCPierluigi Caboni
Pierluigi Caboni
AGArianna Garau
Arianna Garau
Anna CartaAnna Carta
Anna Carta

27 April 2018 in Frontiers in Molecular Neuroscience
Verified
Journal Article
Open access
PDF file
Elzbieta JandaElzbieta Janda
Elzbieta Janda
LBLaura Boi
Laura Boi
Anna CartaAnna Carta
Anna Carta
The role of phagocytosis in the neuroprotective function of microglia has been appreciated for a long time, but only more recently a dysregulation of this process has been recognized in Parkinson’s disease (PD). Indeed, microglia play several critical roles in central nervous system (CNS), such as clearance of dying neurons and pathogens as well as immunomodulation, and to fulfill these complex tasks they engage distinct phenotypes. Regulation of phenotypic plasticity and phagocytosis in microglia can be impaired by defects in molecular machinery regulating critical homeostatic mechanisms, including autophagy. Here, we briefly summarize current knowledge on molecular mechanisms of microglia phagocytosis, and the neuro-pathological role of microglia in PD. Then we focus more in detail on the possible functional role of microglial phagocytosis in the pathogenesis and progression of PD. Evidence in support of either a beneficial or deleterious role of phagocytosis in dopaminergic degeneration is reported. Altered expression of target-recognizing receptors and lysosomal receptor CD68, as well as the emerging determinant role of α-synuclein (α-SYN) in phagocytic function is discussed. We finally discuss the rationale to consider phagocytic processes as a therapeutic target to prevent or slow down dopaminergic degeneration.